期刊文献+

重组人γ-干扰素联合白消安诱导建立小鼠重型再生障碍性贫血模型 被引量:7

Establishment of a severe aplastic anemia mouse model by using recombinant human interferon-gamma plus busulfan
下载PDF
导出
摘要 背景:建立理想的重型再生障碍性贫血动物模型对探究再生障碍性贫血发病机制及筛选有效防治药物尤为重要。目的:应用注射用重组人γ-干扰素联合白消安建立小鼠重型再生障碍性贫血模型。方法:选择健康雌性昆明小鼠60只,随机分为再生障碍性贫血造模组(n=50)和对照组(n=10)。再生障碍性贫血造模组予重组人γ-干扰素1×104 U/d腹腔注射,以白消安18 mg/(kg·d)灌胃,均连续用药7 d;对照组给予同等容量生理盐水灌胃及腹腔注射。比较两组间一般情况、体质量及血细胞计数,并观察再生障碍性贫血造模组小鼠骨髓细胞形态学及骨髓活组织病理学的变化。结果与结论:给药第7天时,再生障碍性贫血造模组小鼠体质量、白细胞、血红蛋白、血小板及网织红细胞计数均较对照组明显下降,差异有显著性意义(P<0.05);骨髓细胞形态学及骨髓活组织病理学检查显示再生障碍性贫血造模组小鼠骨髓增生极度减低,非造血细胞团相对易见,油滴明显增多,脂肪空泡明显。提示联合应用重组人γ-干扰素和白消安能成功建立小鼠再生障碍性贫血模型,该造模方法操作简便,费用低,稳定性好。 BACKGROUND:It is important to establish an ideal mouse model of severe aplastic anemia for investigating the mechanism and finding new therapies for aplastic anemia. OBJECTIVE:To establish a severe aplastic anemia mouse model by using recombinant human interferon-γand busulfan. METHODS:Sixty healthy Kunming female mice were randomly divided into two groups:model group (n=50) and control group (n=10). The model group was given recombinant human interferon-γat a dose of 1×104 U/d by intraperitoneal injection and busulfan at a dose of 18 mg/(kg·d) through stomach feeding for 7 days. The same volume of physiological saline was given to control group. Multi-parameters, including general condition, body weight, blood cellcount, morphology and biopsy of bone marrow were analyzed in two groups. RESULTS AND CONCLUSION:At day 7 after treatment, the weight, white blood cellcount, hemoglobin, blood platelet, reticulocyte count in model group were significantly lower than control group (P〈0.05). Bone marrow smears and biopsy of model group showed marked reduction of bone marrow proliferation and increases of percentages of non-hematopoietic cellclusters and adipose tissue. The oil drop and fat vacuole were apparently seen in the model group. Severe aplastic anemia mouse model can be established by using recombinant human interferon-γand busulfan successful y, which is economic, stable and easy to operate.
出处 《中国组织工程研究》 CAS CSCD 2014年第36期5868-5873,共6页 Chinese Journal of Tissue Engineering Research
基金 珠海市科技计划项目(2013D0401990016)~~
  • 相关文献

参考文献29

二级参考文献141

共引文献204

同被引文献55

  • 1黄继汉,黄晓晖,陈志扬,郑青山,孙瑞元.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004,9(9):1069-1072. 被引量:1319
  • 2孙纪元,王四旺,谢艳华,施新猷.再生障碍性贫血的动物模型实验研究[J].中国实验动物学杂志,2000,10(4):210-212. 被引量:57
  • 3肖纯,黄越燕,黄桂林,朱金华,李大明.环磷酰胺和甲苯合用复制小鼠再生障碍性贫血模型及病理学观察[J].中国比较医学杂志,2005,15(1):7-9. 被引量:16
  • 4毛平,彭盘俐,许力.人脐血单个核细胞体外扩增后植入NOD/SCID小鼠重建多系造血[J].中华器官移植杂志,2006,27(4):231-234. 被引量:13
  • 5Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014; 28(6): 1191-1195.
  • 6Tefferi A, Guglielmelli P, Larson DR, et al. Long-term surviva and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513.
  • 7Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantlY influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011 ;29(23):3179-3184.
  • 8Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9):1960-1963.
  • 9Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24): 22788-22792.
  • 10Kralovics R, Passamonti F, BuserAS, et al. Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005352(17): 1779-1790.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部